Traws Pharma Announces Promising Preclinical Results for Bird Flu Treatment
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled encouraging preclinical results for its experimental antiviral drug, tivoxavir marboxil, in combating H5N1 bird flu. Using a ferret model, widely …
Traws Pharma Announces Promising Preclinical Results for Bird Flu Treatment Read More